IMV.TO - IMV Inc.
| Previous Close | 2.2000 |
| Open | 2.2900 |
| Bid | 2.2800 x 0 |
| Ask | 2.3200 x 0 |
| Day's Range | 2.2000 - 2.3800 |
| 52 Week Range | 1.9800 - 6.6900 |
| Volume | 33,416 |
| Avg. Volume | 129,243 |
| Market Cap | 118.896M |
| Beta (5Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5510 |
| Earnings Date | Mar. 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.44 |
- Thomson Reuters StreetEvents
Edited Transcript of IMV.TO earnings conference call or presentation 31-Mar-20 12:00pm GMT
Q4 2019 IMV Inc Earnings Call
- Simply Wall St.
Does IMV (TSE:IMV) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Business Wire
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
- Business Wire
IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical operations amid the COVID-19 pandemic.
- Business Wire
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
- Zacks
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
- Business Wire
IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV’s heritage across its DPX platform technology.
- Zacks
Will IMV INC (IMV) Report Negative Q4 Earnings? What You Should Know
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Is IMV Inc.'s (TSE:IMV) CEO Paid Enough Relative To Peers?
Fred Ors became the CEO of IMV Inc. (TSE:IMV) in 2016. This analysis aims first to contrast CEO compensation with...
- Simply Wall St.
Did IMV Inc. (TSE:IMV) Insiders Buy Up More Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Thomson Reuters StreetEvents
Edited Transcript of IMV.TO earnings conference call or presentation 8-Nov-19 1:00pm GMT
Q3 2019 IMV Inc Earnings Call
- Simply Wall St.
The IMV (TSE:IMV) Share Price Is Down 56% So Some Shareholders Are Wishing They Sold
Investing in stocks comes with the risk that the share price will fall. And there's no doubt that IMV Inc. (TSE:IMV...
